Morningstar

United Therapeutics Corp UTHR

Stock XNAS Rating as of Oct 1, 2026

News

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

Business Wire Sep 30, 2026, 11:09:00 PM
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

Business Wire Sep 8, 2026, 11:00:00 AM
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

Business Wire Sep 2, 2026, 11:00:00 AM
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

Business Wire Sep 1, 2026, 11:00:00 AM
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

Business Wire Aug 28, 2026, 11:00:00 AM
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

Business Wire Aug 24, 2026, 11:00:00 AM
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

Business Wire Aug 17, 2026, 11:00:00 AM
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

Business Wire Aug 5, 2026, 10:30:00 AM
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

Business Wire Jul 29, 2026, 10:30:00 AM
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

Business Wire Jul 23, 2026, 10:30:00 AM
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026

Business Wire Jul 22, 2026, 11:00:00 AM
United Therapeutics Lung Disease Drug Study Meets Primary Endpoint

Global News Select Mar 30, 2026, 11:50:00 AM
6 stocks and ETFs that these unsung market heroes see outperforming in 2026

MarketWatch Jan 17, 2026, 5:04:00 PM
6 stocks and ETFs that these unsung market heroes see outperforming in 2026

MarketWatch Jan 13, 2026, 3:39:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.